BioInvent has Submitted a CTA for a Phase 1/2a trial of BI-1607, a Novel anti-FcyRIIB Antibody for the Treatment of Patients with Solid Tumors
LUND, SE / ACCESSWIRE / December 8, 2021 / BioInvent International (STO:BINV) BioInvent’s pipeline expanding…
From Phase III Trials to Commercialization Partnerships, MindRank’s AI Drug Development Value Comes into Focus
TMX Group Equity Financing Statistics – September 2026
TMX Group Limited Announces Release Date for Q3 2026 Financial Results and Analyst Conference Call
GMG Announces 48% Increase in Energy Density, Doubling of Cycle Life and 94% Energy Efficiency for 6 Minute Fast Charge
DGTL Holdings Inc. Announces Failure-to-File Cease Trade Order